Bristol-Myers Squibb
BMY
BMY
1,592 hedge funds and large institutions have $64B invested in Bristol-Myers Squibb in 2017 Q2 according to their latest regulatory filings, with 105 funds opening new positions, 574 increasing their positions, 658 reducing their positions, and 87 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
1.13% less ownership
Funds ownership: 70.7% → 69.57% (-1.1%)
2% less funds holding in top 10
Funds holding in top 10: 45 → 44 (-1)
13% less repeat investments, than reductions
Existing positions increased: 574 | Existing positions reduced: 658
Holders
1,592
Holding in Top 10
44
Calls
$1.81B
Puts
$1.51B
Top Buyers
| 1 | +$391M | |
| 2 | +$253M | |
| 3 | +$221M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$196M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$185M |
Top Sellers
| 1 | -$562M | |
| 2 | -$366M | |
| 3 | -$350M | |
| 4 |
Morgan Stanley
New York
|
-$287M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$134M |